Human Genome Sciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1992-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.hgsi.com
A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01
- First Posted Date
- 2007-12-31
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT00583557
- Locations
- 🇺🇸
University of Pittsburgh School of Medicine & ASPH, Pittsburgh, Pennsylvania, United States
🇺🇸Wallace Rheumatic Disease Center, Los Angeles, California, United States
🇺🇸IPC Clinical Research, Ogden, Utah, United States
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2016-12-12
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 865
- Registration Number
- NCT00424476
- Locations
- 🇦🇷
CAICI, Instituto Centralizado de Asistencia e Investigación Clínica Integral, Rosario, Argentina
🇨🇴Fundación Instituto de Reumatología Fernando Chalem, Bogota, Colombia
🇨🇴Centrode de Investigaciones en Reumatologia Especialidades Medicas (CIREEH), Bogotá, Colombia
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2006-12-14
- Last Posted Date
- 2013-08-08
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 933
- Registration Number
- NCT00411385
- Locations
- 🇺🇸
Atlanta Gastroenterology Associates, Atlanta, Georgia, United States
🇺🇸Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 819
- Registration Number
- NCT00410384
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇨🇦Centre for Prognosis Studies in Rheaumatic Diseases, Toronto, Ontario, Canada
🇨🇿Institute of Rheumatology, Prague, Czech Republic
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2013-08-08
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 1331
- Registration Number
- NCT00402428
- Locations
- 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States
🇺🇸Maryland Digestive Disease Center, Laurel, Maryland, United States
🇦🇺Monash Medical Centre, Clayton, Victoria, Australia
Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2006-04-19
- Last Posted Date
- 2013-08-08
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT00315757
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇦🇺Institute of Medical & Veterinary Science, Adelaide, South Australia, Australia
🇺🇸Scripps Clinic Medical Group, Inc., La Jolla, California, United States
A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2005-06-27
- Last Posted Date
- 2013-11-07
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 458
- Registration Number
- NCT00115908
- Locations
- 🇷🇴
Spitalul de Boli Infectioase si Tropicale "Dr. Victor Babes", Bucharest, Romania
🇨🇿Klinika infekcnich nemoci, Hradec Kralove, Czech Republic
🇨🇿Fakultni Thomayerova nemocnice, Prague, Czech Republic
Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral Therapy
- Conditions
- HIV Infections
- First Posted Date
- 2005-06-17
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00114699
- Locations
- 🇺🇸
University Hospitals of Cleveland, Cleveland, Ohio, United States
🇺🇸AIDS Research Alliance, Los Angeles, California, United States
🇺🇸Quest Clinical Research, San Francisco, California, United States
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
- Conditions
- Hepatitis C
- First Posted Date
- 2004-11-24
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT00097435
- Locations
- 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Lymphoma, Non-Hodgkin
- First Posted Date
- 2004-10-27
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Human Genome Sciences Inc.
- Registration Number
- NCT00094848
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States